Work

Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.8507

Authors: Jamie E. Chaft, Daniel Botelho Costa, Alona Muzikansky, Joseph B Shrager, Michael Lanuti, James Huang, Kavitha Ramchandran, Deepa Rangachari, Mark Huberman, Zofia Piotrowska, Mark G. Kris, Christopher G. Azzoli, Lecia V. Sequist, Joel W. Neal

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Stanford Cancer Institute, Stanford Medicine, Stanford University, Harvard University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947467192

Cites:

Cited by: 2

Related to: 10